



Shantha Biotechnics' Inactivated Polio Vaccine (IPV) completes delivery of 20 million doses to the Government of India

***- India is in its fourth year of being polio-free –
- Every second baby in India is vaccinated with Sanofi Pasteur's IPV -***

Hyderabad, India, – October 24, 2017: Sanofi Pasteur, the vaccines division of Sanofi, is proud to announce that since December 2015, its affiliate Shantha Biotechnics has supplied 20 million doses of ShanIPV™ to the Government of India. ShanIPV™ is the only Inactivated Polio Vaccine (IPV) to be locally manufactured and provided to the Indian Government. **Shri K. T. Rama Rao, Hon'ble Minister for Information Technology, Industries and Commerce** flagged off the final shipment from Shantha Biotechnics' manufacturing site in Medchal, Telangana.

Polio is a highly infectious disease caused by a virus. One in 200 infections leads to irreversible paralysis (usually in the legs). Among those paralysed, 5% to 10% die when their breathing muscles become immobilized. There is no cure for polio - it can only be prevented by vaccination. Polio vaccine, given multiple times, can protect a child for life.

Jean-Pierre Baylet, Country Head, Sanofi Pasteur (South Asia), shared that, "Sanofi Pasteur's contribution to India's unparalleled polio success story started when India was still trying to eradicate polio. Since 2015, after one of the most extensive public health campaign in history, Sanofi Pasteur is supporting the Government's efforts to keep India polio-free with millions of doses of ShanIPV™ and Imovax® Polio. Today, every second baby in India is being vaccinated with one of the two Sanofi Pasteur's Inactivated Polio Vaccines (IPV)."

According to the GPEI (Global Polio Eradication Initiative) Endgame Strategic Plan 2013-2018, introducing at least one dose of IPV in current polio eradication programs and completely switching from OPV to IPV in the next few years, is critical to ending polio transmission and improving immunization rates. India is currently in its fourth year of being polio free and its sixth, since the last reported polio case. Once considered the epicenter of polio, the status of being polio-free is a tremendous accomplishment for India. The drive to eradicate polio has been momentous and historical, given that there are more than 170 million babies in the country, from diverse States, faiths, communities, social and economic backgrounds.

Dr. Shailesh Ayyangar, Managing Director - India and Head - South Asia, Sanofi, said, "The most significant impact that Sanofi has made on healthcare in India is by supporting the Government's efforts to eradicate polio. Sanofi Pasteur, through its affiliate, Shantha Biotechnics, was the first company to partner with the Indian Government, directly and via the UNICEF, in supplying IPV to achieve the goal of a polio-free world."

For the past 25 years, Sanofi Pasteur, along with the WHO's Global Polio Eradication Initiative (GPEI), Rotary International, UNICEF, the GAVI Alliance, and more recently, the Bill and Melinda Gates Foundation, has played a major role in slashing the number of polio cases by 99%.

Commenting on the milestone, **Dr. Mahesh Bhalgat, Executive Director and COO, Shantha Biotechnics** said, “We are proud to be an integral part of India’s fight against polio, and the 20 million dose milestone reflects our endeavor to support the Government in this mission. We recognized the critical role that ShanIPV™ would play in the eradication of polio and so, we increased our local production capacity to make the vaccine available for babies all across India. Going forward, Shantha will continue to wholly support the government in its polio eradication efforts.”

Today, polio is only routinely transmitted from person to person in two countries - Afghanistan and Pakistan.

About Shantha Biotechnics

Shantha Biotechnics, which was acquired by Sanofi Pasteur Holding in 2009, is a biotechnology pioneer from the emerging countries, founded by Dr. K I Varaprasad Reddy in 1993 in Hyderabad, India. Shantha is a fully integrated biotechnology company involved in R&D, manufacturing and marketing.

Shantha’s mission is to develop, produce and market human healthcare products that are affordable and meet the highest International standards. Shantha’s products complement Sanofi Pasteur’s vaccine portfolio. Four of its licensed vaccines are WHO-prequalified: Shan5™ pediatric vaccine, Shanchol™ cholera vaccine, Shanvac-B® hepatitis B vaccine, and ShanTT™ tetanus vaccine. Sanofi Pasteur and Shantha are also developing a new pediatric combination vaccine based on Shan5™ that will incorporate Sanofi Pasteur’s Inactivated Polio Vaccine (IPV) in order to secure polio eradication.

About Sanofi

Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.

With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

Sanofi, Empowering Life

Sanofi Pasteur, the vaccines division of Sanofi, provides more than 1 billion doses of vaccine each year, making it possible to immunize more than 500 million people across the globe. A world leader in the vaccine industry, Sanofi Pasteur produces a portfolio of high quality vaccines that matches its areas of expertise and meets public-health demand. The company's heritage, to create vaccines that protect life, dates back more than a century. Sanofi Pasteur is the largest company entirely dedicated to vaccines. Every day, the company invests more than EUR 1 million in research and development. For more information, please visit: www.sanofipasteur.com or www.sanofipasteur.us

Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar

expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi's ability to benefit from external growth opportunities and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic conditions, the impact of cost containment initiatives and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2016. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

Contacts:

India Media Relations

Aparna Thomas

Tel. +91-22-28-03-21-69

aparna.thomas@sanofi.com

Shantha Biotechnics

Phalgun Hari Jandhyala

Tel. +91-73306-04488

PhalgunHari.Jandhyala@sanofi.com